In a recent segment of MidasLetter Live, Canntab Therapeutics (CSE:PILL) CEO Jeff Renwick and CFO Richard Goldstein spoke to Midas about the work the company has done in recent months to double the company’s valuation.
During the segment, Renwick and Goldstein provided an overview of what Canntab does, which is to transform cannabis resins into hard tablet/pill form. The company is developing these products as they await for Health Canada approval of hard tablets as a viable form of oral consumption of cannabis. To Canntab, the value of hard tablets is that they protect cannabinoids from degradation as they pass through the digestive system. They also offer a more stable delivery method.
In terms of revenue, Canntab is generating licensing fees from their deal with Emblem (TSXV:EMC,OTCQX:EMMBF), a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada. Under the licensing agreement, Emblem has agreed to develop and market three of Canntab’s products. Canntab also expects to conduct its first product sales in 2019.
The company is focused on developing both THC and CBD products. For the latter, Goldstein emphasized the importance of using full-spectrum CBD oils, which will now be available following legalization. Full-spectrum CBD can be extracted from the hemp plant. Up until now, hemp oil could only be extracted from the hemp seed, which does not have as much CBD value. Canntab plans to encapsulate full-spectrum CBD oil into tablets and market that product, serving the medical market particularly.
The Canntab executives emphasized that despite the potential innovations on the horizon for cultivating cannabinoids, whether it be through the cannabis plant or in the laboratory, there will always be a need for effective delivery methods, and that is what Canntab can provide.
To watch the full interview, click here.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).